Research

Efficiency of 7.2% hypertonic saline hydroxyethyl starch 200/0.5 versus mannitol 15% in the treatment of increased intracranial pressure in neurosurgical patients – a randomized clinical trial [ISRCTN62699180]

Lilit Harutjunyan1, Carsten Holz2, Andreas Rieger2, Matthias Menzel3, Stefan Grond4 and Jens Soukup5

1Anaesthesiologist, Department of Anesthesia and Critical Care, Martin-Luther-University Halle-Wittenberg, Halle, Germany
2Neurosurgeon, Department of Neurosurgery, Martin-Luther-University Halle-Wittenberg, Halle, Germany
3Head, Department of Anesthesia and Critical Care, Klinikum Wolfsburg, Wolfsburg, Germany
4Professor of Anesthesiology and Pain Therapy, Department of Anesthesia and Critical Care, Martin-Luther-University Halle-Wittenberg, Halle, Germany
5Anaesthesiologist and Intensivist, Department of Anesthesia and Critical Care, Martin-Luther-University Halle-Wittenberg, Halle, Germany

Corresponding author: Lilit Harutjunyan, arlilith@yahoo.de

Received: 6 May 2005 Revisions requested: 6 Jun 2005 Revisions received: 14 Jun 2005 Accepted: 17 Jun 2005 Published: 9 Aug 2005

Critical Care 2005, 9:R530-R540 (DOI 10.1186/cc3767)
This article is online at: http://ccforum.com/content/9/5/R530
© 2005 Harutjunyan et al.; licensee BioMed Central Ltd.
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Introduction This prospective randomized clinical study investigated the efficacy and safety of 7.2% hypertonic saline hydroxyethyl starch 200/0.5 (7.2% NaCl/HES 200/0.5) in comparison with 15% mannitol in the treatment of increased intracranial pressure (ICP).

Methods Forty neurosurgical patients at risk of increased ICP were randomized to receive either 7.2% NaCl/HES 200/0.5 or 15% mannitol at a defined infusion rate, which was stopped when ICP was < 15 mmHg.

Results Of the 40 patients, 17 patients received 7.2% NaCl/HES 200/0.5 and 15 received mannitol 15%. In eight patients, ICP did not exceed 20 mmHg so treatment was not necessary. Both drugs decreased ICP below 15 mmHg (p < 0.0001); 7.2% NaCl/HES 200/0.5 within 6.0 (1.2–15.0) min (all results are presented as median (minimum-maximum range)) and mannitol within 8.7 (4.2–19.9) min (p < 0.0002). 7.2% NaCl/HES 200/0.5 caused a greater decrease in ICP than mannitol (57% vs 48%; p < 0.01). The cerebral perfusion pressure was increased from 60 (39–78) mmHg to 72 (54–85) mmHg by infusion with 7.2% NaCl/HES 200/0.5 (p < 0.0001) and from 61 (47–71) mmHg to 70 (50–79) mmHg with mannitol (p < 0.0001). The mean arterial pressure was increased by 3.7% during the infusion of 7.2% NaCl/HES 200/0.5 but was not altered by mannitol. There were no clinically relevant effects on electrolyte concentrations and osmolarity in the blood. The mean effective dose to achieve an ICP below 15 mmHg was 1.4 (0.3–3.1) ml/kg for 7.2% NaCl/HES 200/0.5 and 1.8 (0.45–6.5) ml/kg for mannitol (p < 0.05).

Conclusion 7.2% NaCl/HES 200/0.5 is more effective than mannitol 15% in the treatment of increased ICP. A dose of 1.4 ml/kg of 7.2% NaCl/HES 200/0.5 can be recommended as effective and safe. The advantage of 7.2% NaCl/HES 200/0.5 might be explained by local osmotic effects, because there were no clinically relevant differences in hemodynamic clinical chemistry parameters.

Introduction

The development or presence of secondary brain injury in patients with intracranial pathology has been associated with increased morbidity and mortality. An increase in intracranial pressure (ICP) accompanied by a low cerebral perfusion pressure (CPP) should therefore be avoided in these patients.

BBB = blood-brain barrier; CPP = cerebral perfusion pressure; GCS = Glasgow Coma Score; ICH = intracerebral hemorrhage; ICU = intensive care unit; SAH = subarachnoid hemorrhage; SAPS = simplified acute physiology score; SHT = severe head trauma; SpO2 = peripheral oxygen saturation
Several clinical studies have demonstrated that outcome is improved by adequate pharmacological or neurosurgical treatment optimizing ICP [1-3]. According to established treatment guidelines, an ICP >20 mmHg and a CPP <60 mmHg are considered critical [4-8]. Early recognition of such critical episodes by multimodal neuromonitoring, and selection of an effective and safe drug for treatment are essential for neuroprotection.

Osmotherapy has been used since the early 20th century to treat increased ICP. The physiological basis and concept of osmotherapy was first published in 1919 [9]. Intravenous infusion of mannitol is considered to be the 'gold standard' for the treatment of increased ICP. Barbiturates and TRIS buffer are still used as alternative treatments, although their use in clinical practice is limited by cardiovascular and metabolic side effects [10-13]. In addition, experimental and clinical evidence has shown that 'small volume resuscitation' has a positive effect in the treatment of increased ICP in trauma patients [14-16].

Experimentally, intravenous application of hypertonic saline increases global cerebral perfusion as well as the right-shifted oxygen dissociation curve, both with consecutive improvement of oxygen delivery. At the same time, an increase of cerebral compliance and decrease in ICP occur by decrease of the brain edema [17].

Although several experimental and clinical studies have investigated the effects of hypertonic saline or mannitol on ICP, only a few studies comparing these drugs in neurosurgical patients have been published [18-22]. Furthermore, there are no clinical data available for recommendation of an 'effective dose' of hypertonic saline in clinical practice.

The purpose of this study was to compare the efficacy and safety of 7.2% NaCl/HES 200/0.5 and mannitol 15% in neurosurgical patients with increased ICP. This study focuses on the effects of both drugs on ICP, CPP, mean arterial pressure (MAP), hematocrit, serum sodium and osmolarity. Furthermore, we attempted to recommend an effective dose for the application of hypertonic saline.

**Methods**

After approval by the local ethics committee and written informed consent being obtained from the patients' legal relatives, neurosurgical patients with severe neuronal damage (e.g. cerebral trauma, spontaneous intracerebral bleeding or subarachnoidal bleeding) were enrolled in this prospective randomized study. The patients were randomized to receive either 7.2% NaCl/HES 200/0.5 (HyperHAES®, Fresenius Kabi Deutschland GmbH, Bad Homburg) or mannitol (Osmofundin® 15%-N, B. Braun Melsungen AG, Melsungen, Germany), to treat increased ICP.

Inclusion criteria were: age >18 years, severe brain damage (Glasgow Coma Score <8) with cerebral edema – visualized by CT scan and continuous monitoring of ICP. Exclusion criteria were: elevated ICP due to space-occupying lesions with indication for neurosurgical intervention (e.g. bleeding, hydrocephalus), severe renal failure, metabolic disorders, initial serum sodium >150 mmol/l and initial serum osmolarity >320 mosm/kg.

**Standard treatment protocol**

All patients were intubated and received pressure-controlled mechanical ventilation (BiPAP), etCO\textsubscript{2} 4.2–4.8 kPa, FiO\textsubscript{2} 0.3–1.0). Care was taken to keep the arterial partial oxygen pressure above 15 kPa, the hemoglobin concentration above 5.5 mmol/l and the CPP above 70 mmHg. If necessary, blood pressure was supported with vasopressor therapy. Blood glucose was adjusted to values between 6–8 mmol/l by continuous application of human insulin. Patients' core temperature was measured via the bladder, with a target temperature of 36.0–37.0°C. If the core temperature exceeded 37.0°C, external cooling blankets were used to cool the patient, otherwise patients were covered either with an additional blanket or with an active heating blanket (Bair Hugger; Augustine Medical, Eden Prairie, MN, USA).

Analgosedation and continuous patient monitoring were managed according to the standards of the Department of Anesthesiology and Critical Care at the Martin-Luther-University Halle-Wittenberg, Germany. Analgosedation at days 1–4 was performed using propofol and sufentanil or remifentanil. Thereafter, midazolam and sufentanil were administered. The standard monitoring included electrocardiogram, invasive arterial blood pressure, central venous pressure, peripheral oxygen saturation (SpO\textsubscript{2}) and intraparenchymal ICP measurement (Codman Microsensor ICP Monitoring System; Codman & Shurtleff Inc, Raynham, MA, USA).

An increase in ICP was treated first by deepening the sedation and analgesia by titrating the medication and adjusting to adequate ventilator settings. If ICP exceeded the 20 mmHg threshold for more than 5 min, the study medication (mannitol or 7.2% NaCl/HES 200/0.5 [herein referred to as '7.2% hypertonic saline' or 'hypertonic saline']) was infused via the central venous line using an automated infusion system at a defined infusion rate. The infusion was stopped when ICP was reduced to <15 mmHg, defined as the treatment goal. However, in the case of sustained ICP problems (ICP >15 mmHg or CPP <70 mmHg) after these measures, bolus applications of thiopentone (maximum single bolus: 5 mg/kg) were allowed. In these patients, the possibility of a space-occupying lesion was excluded by CT scan.

**Data acquisition and statistical analysis**

Mean arterial blood pressure, heart rate, SpO\textsubscript{2}, ICP and calculated CPP were continuously measured. Analysis of these
parameters was performed at the following time points: initiation of infusion; after termination of infusion (ICP <15 mmHg achieved); 10 min after terminating infusion; 30 min after terminating infusion; and 60 min after terminating infusion. Serum sodium level and hematocrit were measured every 4 h and the serum osmolarity every 12 h. The values taken before the therapy, as well as the maximum values subsequently achieved, were analyzed. Individual outcomes were assessed at the end of stay in the intensive care unit (ICU) using the differentiation between survivors and non-survivors.

The random code for group assignment was generated by computer. The software package Stat View 4.0 (Abacus Concepts Inc, Berkeley, CA, USA) was used for all statistical calculations. All demographic data are presented as mean ± SD. The clinical values in both groups were not normally distributed. Results are presented as median (minimum-maximum range). Groups were compared using the non-parametric Mann-Whitney U-Test and the Wilcoxon Signed Rank was employed to analyze the effect of the medication used within each group; \( p < 0.05 \) was regarded as statistically significant and computed significance levels are given.

Results

A total of 40 neurosurgical patients were recruited according to the inclusion criteria and randomized to receive either 7.2% NaCl/HES 200/0.5 (\( n = 17 \)) or mannitol 15% (\( n = 15 \)) to treat increased ICP. Only 32 patients were evaluated since in eight patients, ICP did not exceed 20 mmHg, therefore no study medication was administered.

Demographic data of all analyzed patients are summarized in Table 1. There were no significant differences between the two groups. No relevant clinical characteristics were revealed in the eight patients not undergoing osmotic therapy.

Analgosedation was started in all patients using our standard protocol. In four patients in the 7.2% hypertonic saline group and five patients in the mannitol group, propofol was substituted by thiopental because of sustained ICP problems.

Heart rate and blood pressure

The average baseline heart rate was 78 (58–95) bpm in the mannitol and 76 (52–92) bpm in the hypertonic saline group (\( p = \text{NS} \)). The infusion of study medication produced no clinically relevant changes in heart rate and no arrhythmias.

The initial MAP was 84 (68–92) mmHg in the mannitol group and 82 (64–98) mmHg in the hypertonic saline group (\( p = \text{NS} \)). Maximal changes could be analyzed in the mannitol group after 10 min (83 (69–105) mmHg) and in patients receiving hypertonic saline after 30 min (85 (74–98) mmHg) (Fig. 1, Table 2).

The individual maximum increase of MAP during the observation time after infusion of mannitol was 5.8% to 88 (72–106) mmHg and after infusion of hypertonic saline was 7.6% to 85 (74–98) mmHg. The time of the maximal increase was individual for each patient as well.

Demographic data of analyzed patients are summarized in Table 1. There were no significant differences between the two groups. No relevant clinical characteristics were revealed in the eight patients not undergoing osmotic therapy.

Heart rate and blood pressure

The average baseline heart rate was 78 (58–95) bpm in the mannitol and 76 (52–92) bpm in the hypertonic saline group (\( p = \text{NS} \)). The infusion of study medication produced no clinically relevant changes in heart rate and no arrhythmias.

The initial MAP was 84 (68–92) mmHg in the mannitol group and 82 (64–98) mmHg in the hypertonic saline group (\( p = \text{NS} \)). Maximal changes could be analyzed in the mannitol group after 10 min (83 (69–105) mmHg) and in patients receiving hypertonic saline after 30 min (85 (74–98) mmHg) (Fig. 1, Table 2).

The individual maximum increase of MAP during the observation time after infusion of mannitol was 5.8% to 88 (72–106) mmHg and after infusion of hypertonic saline was 7.6% to 85 (74–98) mmHg. The time of the maximal increase was individual for each patient as well.

**Table 1**

Demographic data of analyzed patients

|                     | Mannitol 15% (\( n = 15 \)) | 7.2% NaCl/HES 200/0.5 (\( n = 17 \)) |
|---------------------|----------------------------|-----------------------------------|
| Age                 | 47 ± 16                    | 47 ± 16                           |
| Weight              | 89 ± 27                    | 87 ± 24                           |
| Gender, M/F         | 8/7                        | 9/8                               |
| Initial GCS         | 5.8 ± 1.4                  | 6 ± 1.3                           |
| SAPS score          | 42.5 ± 13                  | 39.6 ± 9.6                        |
| Days on ICU         | 23.3 ± 14.8                | 22.8 ± 15.5                       |
| Basic illness       |                            |                                   |
| SAH                 | 5                           | 4                                 |
| Brain infarct       | 4                           | 3                                 |
| Isolated SHT III*   | 4                           | 6                                 |
| ICH                 | 1                           | 3                                 |
| Other               | 1                           | 1                                 |
| Surgical intervention | 13                         | 13                                |

7.2% NaCl/HES 200/0.5, 7.2% hypertonic saline hydroxyethyl starch 200/0.5; GCS, Glasgow Coma Score; ICH, intracerebral hemorrhage; ICU, intensive care unit; SAPS, simplified acute physiology score; SHT, severe head trauma.
Prior to administration of the study medication, the mean ICP was 23 (19–30) mmHg in the mannitol group and 22 (19–31) mmHg in the hypertonic saline group (p = NS). After infusion with mannitol, the ICP decreased to 14 (7–20) mmHg and after infusion with hypertonic saline it decreased to 15 (8–18) mmHg (p < 0.0001). This effect was achieved within 8.7 (4.2–19.9) min by mannitol and 6.0 (1.2–15.0) min by hypertonic saline (p < 0.0001). The lowest ICP was 12 (6–19) mmHg in the mannitol and 10 (6–14) mmHg in the hypertonic saline group (p < 0.05), observed 30 min after the end of infusion. Thus, the maximum decrease in ICP produced by hypertonic saline was 57% and that of mannitol 48%. Sixty minutes after the end of infusion, the ICP in the hypertonic saline group was still lower than that of the mannitol group (11 (5–18) mmHg; vs 14 (7–20) mmHg; p < 0.005) (Fig. 2, Table 2).

Prior to administration of study medication, the mean CPP was 61 (47–71) mmHg in the mannitol and 60 (39–78) mmHg in the hypertonic saline group (p = NS; Fig. 3). At the end of infusion, a significant increase of CPP to 70 (50–79) mmHg after mannitol infusion (p < 0.0001) and 72 (54–85) mmHg after hypertonic saline infusion (p < 0.0001) occurred. This improvement was maintained during the whole study period. The maximal increase in CPP occurred in both groups after 30 min (mannitol +18%; hypertonic saline +27%; p < 0.05). CPP was significantly higher in the hypertonic saline group (p < 0.01, Fig. 3, Table 2) 30 and 60 min after the end of infusion.

The 15 patients in the mannitol group had a total of 53 episodes of increased ICP exceeding 20 mmHg requiring infusion of study medication (3.5 treatments/patient). For 49 of these episodes (92.5%), infusion of mannitol was effective and reduced ICP to <15 mmHg within 8.7 (4.2–19.9) min. For one episode, mannitol produced a delayed effect, appearing 20 min after application of a total of 235 ml mannitol (2.6 ml/kg). In three episodes, however, ICP could not be reduced below 15 mmHg by an infusion of up to 2.1 ml/kg of mannitol. In two of these patients, thiopental was given intravenously at up to 3 mg/kg and in one patient a unilateral decompressive craniectomy was performed.

In the 17 patients in the hypertonic saline group, 57 periods of increased ICP occurred (3.3 treatments/patient). 7.2% NaCl/HES 200/0.5 was effective in 55 episodes (96.5%), reducing ICP to <15 mmHg within 6.0 (1.2–15.0) min. In one episode, mannitol produced a delayed effect, appearing 20 min after application of a total of 235 ml mannitol (2.6 ml/kg). In three episodes, however, ICP could not be reduced below 15 mmHg by an infusion of up to 3.1 ml/kg of hypertonic saline. Finally, mild hyperventilation (etCO₂ ~28–30 mmHg) achieved the target ICP value <15 mmHg.
The median dose of mannitol (145 (70–332) ml/application; 1.8 (0.45–6.5) ml/kg) required to reduce ICP below 15 mmHg was significantly higher than that of hypertonic saline (100 (35–250) ml/application; 1.4 (0.3–3.1) ml/kg). Repeated administration of mannitol caused an increase of the required single dose in six out of 15 patients (40%) and a decrease in two patients (13%). Repeated administration of hypertonic saline caused an increase of the required single dose in two patients (12%) and a decrease in seven patients (41%).

Clinical chemistry
Hematocrit was not significantly changed by infusion of mannitol (0.3 (0.27–0.42) vs 0.29 (0.26–0.40)) and hypertonic saline (0.29 (0.24–0.37) vs 0.29 (0.24–0.36)). A temporary, but statistically significant increase of serum sodium occurred after infusion of the hypertonic saline from 143 (136–148) mmol/l to 148 (144–153) mmol/l (p < 0.001). Serum osmolarity increased significantly after infusion of hypertonic saline: 284 (273–300) mosm/kg to 300 (284–319) mosm/kg (p < 0.001), as well as after infusion of mannitol: 286 (270–315) mosm/kg to 295 (278–327) mosm/kg (p < 0.001).

Outcome
Ten patients (58.8%) assigned to the group receiving hypertonic saline survived, the remaining seven patients died (41.2%). In the group with the mannitol treatment, six patients survived (40.0%) and nine patients died (60.0%). The chi-square test revealed no statistical significance.

In patients who survived, a lower dose of the osmotic agent had been administered. Survivors in the hypertonic saline group received a significant lower dose of 1.4 (0.32–2.8) ml/kg hypertonic saline. In non-survivors, the dosage given was 1.7 (0.9–3.1) ml/kg (p < 0.05). In the mannitol group, patients who survived received 1.7 (0.5–3.4) ml/kg mannitol versus 1.9 (1.0–6.5) ml/kg mannitol in patients who died (p = NS). Therefore, a statistical significance regarding the influence of the specific osmolarity, either of hypertonic saline or mannitol, given with each treatment, on changes of the cerebral hemodynamics (ICP, CPP) or patients’ individual outcomes could not be analyzed.

Discussion
The strong relationship between incidence of increased ICP and outcome in patients with neuronal damage emphasizes the vulnerability of the injured brain and the need for adequate...
Critical Care Vol 9 No 5 Harutjunyan et al.

The management of severely injured neurosurgical patients has changed over recent decades, especially regarding the introduction and acceptance of clinical guidelines among neurosurgeons and intensivists [4,10,23,24]. It has become a generally accepted treatment goal to keep the CPP above 70 mmHg, because episodes of CPP <60 mmHg or ICP >20 mmHg are associated with a worse outcome [6-8]. These goals are incorporated into current treatment protocols, which are constantly analyzed with regards to their efficacy and feasibility, and updated accordingly. Osmotic agents are important components of all treatment protocols, especially mannitol as it is a well-established treatment for increased ICP following brain injury. Surveys of the critical care management of head-injured patients show that 83% of the centers in the United States and 100% of the centers in the United Kingdom used mannitol to control ICP [25-27]. The clinical use of mannitol is, however, limited by renal complications and the fast increase of the osmotic gradient followed by its reversal due to disruption of the blood-brain barrier (BBB) [28-31]. Furthermore, mannitol (at concentrations which may be reached in clinical conditions) and the hyperosmotic stress itself can activate the process of apoptotic cell death [32].

Recent data have demonstrated different osmotic effects of mannitol. Videen and co-workers [33] observed that after administration of 1.5 g/kg bolus of mannitol in six patients with acute complete middle cerebral artery infarctions, the brain in the non-infarcted hemisphere shrank more than in the infarcted hemisphere. This may increase the inter-hemispheric pressure difference and worsen tissue shift [33].

Hypertonic saline is an interesting alternative to mannitol, because there is experimental and clinical evidence that it can reduce ICP and improve CPP [34-39]. Experimental studies in animals suffering from a combination of hemorrhagic shock and head trauma demonstrated a significant reduction of ICP, an improvement of CPP and/or a reduction of brain edema [34-36,40,41].

The efficacy of hypertonic saline after isolated brain injury, however, has rarely been investigated. Qureshi et al. [22] examined different concentrations of hypertonic saline (23.4%, 3.0%) versus mannitol after isolated experimental intracerebral hemorrhage in a canine model. The acute effects on ICP and CPP were most prominent after infusion of hypertonic saline 23.4%, but were better sustained after infusion of
Hypertonic saline 3%. The water content was highest after mannitol infusion in most regions of the brain, especially in the white matter ipsilateral to the hematoma. The authors speculated that these results were due to a certain permeability of the BBB. The most positive effect on water content was seen after hypertonic saline 3% [22].

Berger et al. [42] compared the efficacy of hypertonic saline and mannitol to reduce ICP after a combination of two different neuronal injuries. Initially, a cold-induced focal lesion was used to induce a vasogenic brain edema in rabbits, then intracranial hypertension was induced by a further inflation of an epidural balloon. The authors demonstrated that hypertonic solution as well as mannitol can reduce the ICP efficiently. After the first application, the effect of mannitol was enhanced compared with the hypertonic solution (98 ± 14 min vs 189 ± 27 min; \( p < 0.054 \)), but became the same after repeated applications. It is remarkable that mannitol was more effective in decreasing the water content in brain tissue in the traumatized hemisphere, whereas hypertonic solution lowered the water content in the contralateral brain tissue. An accumulation of mannitol could occur, followed by a possible reversal of the local osmotic gradient. These different effects on brain tissue could be an explanation for the failed therapeutic efficiency after mannitol and emphasized the advantages of hypertonic solutions [42]. Furthermore, Prough et al. observed a higher regional cerebral blood flow in dogs with induced intracerebral hemorrhage after hypertonic saline without any increase of the CPP [43].

The positive effect of 7.2% hypertonic saline on ICP has also been demonstrated in several clinical studies investigating patients with therapy-refractory ICP increase due to isolated brain injury but without hemorrhagic shock [21,44-46]. Hypertonic saline had no effects on MAP in these euvoalaemic patients [46].

Schwarz et al. [47] evaluated the efficacy of hypertonic saline hydroxyethyl starch 7.55% in comparison with mannitol 20% in stroke patients with increased ICP. Hypertonic saline hydroxyethyl starch was effective in all, mannitol in only 70% of patients. The maximum ICP decrease was seen 25 min after the start of hypertonic saline infusion and 45 min after the start of mannitol infusion. There was no constant effect on CPP in the hypertonic saline group, whereas CPP rose significantly in the mannitol-treated group. The authors concluded that hypertonic saline hydroxyethyl starch seems to lower ICP more.
effectively but does not increase CPP as much as mannitol [47].

Hypertonic saline has also been used to reduce ICP in patients with brain tumors or subarachnoid hemorrhage. Suarez et al. [48] reported a significant decrease of ICP and increase of CPP in these patients, when application of mannitol had been previously unsuccessful. Similar results were observed by Horn et al. in patients with traumatic brain injury and subarachnoidal hemorrhage, where hypertonic saline 7.5% adequately reduced ICP after mannitol therapy had failed [44].

Based on these findings, patients with isolated head trauma can also be expected to benefit from hypertonic saline. This patient population covers some specific patho-physiological conditions, characterized by diffuse axonal injuries, hemorrhages, and necrotic and edematous tissue, which can lead to different therapeutic strategies and a failed positive effect of hypertonic saline compared with patients with other intracranial mass lesions [49,50]. Munar et al. [51] investigated the acute effects of 7.2% hypertonic saline on ICP, cerebral blood flow and systemic hemodynamics in patients with moderate and severe traumatic brain injury during the first 72 h after injury. Hypertonic saline significantly reduces ICP without changes in MAP and relative global cerebral blood flow, expressed as 1/AVDO₂. These results suggest that hypertonic saline decreases ICP by means of an osmotic mechanism [51].

Not all studies, however, reported positive effects of hypertonic saline on ICP, especially if hypertonic saline was infused continuously. Qureshi et al. analyzed the effect of continuous administration of hypertonic saline 2% or 3% in patients with head trauma. They reported a higher in-hospital mortality rate in patients receiving hypertonic solutions and described no favorable impact on the rate of necessary medical interventions during the patient’s treatment in the ICU. The influence of hypertonic saline on the supposedly disrupted BBB after head injury was mainly used to explain the failed effect. A disrupted BBB can lead to an accumulation of sodium resulting in an reversal of the osmotic gradient with concomitant increase of ICP [52]. However, Hartl et al. demonstrated a reduced water content in areas with a disturbed BBB in a model with or without a focal cryogenic brain lesion and hemorrhagic shock [53].

Our results showed that bolus application of either study medication, mannitol 15% or hypertonic saline 7.2%, significantly decreases ICP and increases CPP (Table 2). The effect of hypertonic saline on ICP was significantly better than that of mannitol. Clinically important effects of both drugs on MAP could not be determined, although some statistically significant differences were observed at a few measurement points. Therefore, it can be concluded that local cerebral dehydration is the main mechanism of both substances in decreasing ICP and optimizing CPP. The higher potency of hypertonic saline suggests that its local effect is more clearly pronounced.

However, the mechanisms whereby hypertonic solutions reduce ICP are multifactorial and are still discussed with some controversy. The main principle seems to be the 'local dehydration' of brain tissue drawing water from parenchyma to the intravascular space following an osmotic gradient [54]. Comparing this with the osmotic effect of mannitol, a second mechanism to explain the effect of the ICP-reduction must exist. This hypothesis is supported by the results of Berger et al. [42]. He found, in rats with induced head injury, a similar positive effect on ICP with regards to the amount and duration of the decrease, but a higher CPP in the rats receiving mannitol. Contrary to our results, the MAP increased after hypertonic saline, whereas the MAP temporarily decreased after mannitol. The authors hypothesized that the different effects of the two solutions are the result of a selective permeability of the BBB and/or the different reflection coefficients. A disrupted BBB would have to be the result of an accumulation of both solutions in the brain tissue. Therefore different mechanisms of local cerebral dehydration must exist [42]. These hypotheses are supported by the results of Worthley et al. and Kaufmann et al. Both working groups demonstrated that the ICP-decreasing effect is limited after repeated bolus applications of mannitol, but a further application of hypertonic saline lead to a further ICP reduction [55,56]. However, a direct vasodilatation of pial vessels [57-59], the reduction of blood viscosity due to enhancement of the intravascular volume, the rapid absorption of cerebrospinal fluid and restoration of the normal osmotic potentials are other effects to positively affect the ICP [60,61]. Our results only support the hypothesis about the local dehydration of brain tissue. Systemic hemodynamic effects for the given dosage couldn’t be demonstrated, but the decreased ICP leads to the improved CPP. All homeostatic side effects after hypertonic saline, for instance hypernatremia and increased serum osmolarity, are temporary and without systemic hemodynamic side effects. Such complications as described in the literature, emphasize cardiac failure with lung edema, metabolic acidosis, coagulopathy subdural hematoma and central pontine myolysis as the most important [22,40,48]. With the intention of limiting the side effects of changes in electrolytes and osmolarity, a standardized laboratory measurement procedure is needed.

The substantial difference in the design of the present and a comparable study is the fact that we did not administer a fixed total dose, but infused the study medication at a defined infusion rate until ICP decreased to <15 mmHg, the primary goal of our treatment. No clinical study has so far identified an exact dose-effect relationship for hypertonic saline. Only one comparable clinical study confirms the superiority of 2.0 ml/kg of hypertonic saline 7.5% over mannitol 20% in head-injured patients [21]. This study concluded that 2 ml/kg of 7.2%
NaCl/HES 200/0.5 can be recommended as an effective dose to reduce increased ICP [21]. In our study, an average dose of 1.5 ± 0.6 ml/kg of hypertonic saline adequately reduced ICP below 15 mmHg. Furthermore, because of our application mode with an defined application rate and a target ICP of <15 mmHg we could demonstrate a failed influence of the osmotic load given with each treatment.

Regardless of all positive effects in our study, there are some limitations that need to be discussed, most of all, the small patient population of each group and the heterogeneity in the underlying neurological illness. The primary intention of our study was pragmatic and adjusted on the typical clinical routine. However, we included neurosurgical patients with severe neuronal damage independent from the individual pathogenesis. To compensate for this to a certain degree, we used a randomized study design. Furthermore, until now there have been only limited data available for comparison of these two osmotic agents in a clinical setting. A small amount of evidence is available that hypertonic saline has some advantages compared with mannitol in the treatment of patients with intracranial hypertension after trauma, subarachnoid bleeding or stroke [21,47,62,63].

**Conclusion**

7.2% NaCl/HES 200/0.5 and mannitol 15% are effective and safe drugs in the treatment of increased ICP, although 7.2% NaCl/HES 200/0.5 is more effective than mannitol. A dose of 1.4 ml/kg can be recommended as an initial dose. The advantage of hypertonic saline can be explained by individual local osmotic effects, because no relevant systemic changes occur. The observed effects on electrolytes and plasma osmolarity are not significantly different between the two osmotic drugs and have no clinical relevance here. Further experimental and clinical research is required to evaluate the optimal administration regime, the best treatment strategies adapted to the individual patient’s needs and the impact on patients’ morbidity and mortality.

**Key messages**

- 7.2% NaCl/HES 200/0.5 is more effective than mannitol in the treatment of increased ICP
- A dose of 1.4 ml/kg 7.2% NaCl/HES 200/0.5 can be recommended as an initial dose
- The local dehydration of brain tissue after application of 7.2% NaCl/HES 200/0.5 seems to be the primary mechanism for the improved CPP

**Authors’ contributions**

All of the authors were involved in designing the study and collecting data. JS and LH were involved in the statistical analysis. SG revised the article and was responsible for translation into English. All authors read and approved the final manuscript.

**Acknowledgements**

The authors are grateful to the intensive care nursing staff who cared for the patients and followed the study protocol.

**References**

1. Lang EW, Chesnut RM: Intracranial pressure and cerebral perfusion pressure in severe head injury. New Horiz 1995, 3:400-409.
2. Chesnut RM: Medical management of severe head injury: present and future. New Horiz 1995, 3:581-593.
3. Caroli M, Locatelli M, Campanella R, Balbi S, Martinelli F, Arienta C: Multiple intracranial lesions in head injury: clinical considerations, prognostic factors, management, and results in 95 patients. Surg Neurol 2001, 56:82-88.
4. Procaccio F, Stocchetti N, Citeriore G, Berardino M, Beretta L, Della Corte F, D’Avella D, Brambilla GL, Delﬁni R, Servadei F, Tomei G: Guidelines for the treatment of adults with severe head trauma (part II). Criteria for medical treatment. J Neurosurg Sci 2000, 44:11-18.
5. Vukic M, Negovetic L, Kovac D, Ghajar J, Glavic Z, Goepke Z: Gopcevic A: The effect of implementation of guidelines for the management of severe head injury on patient treatment and outcome. Acta Neurochir (Wien) 1999, 141:1203-1208.
6. Rosner MJ, Rosner SD, Johnson AH: Cerebral perfusion pressure: management protocol and clinical results. J Neurosurg 1995, 83:949-962.
7. Rosner MJ: Introduction to cerebral perfusion pressure management. Neurosurg Clin N Am 1995, 6:761-773.
8. Rosner MJ, Daughton S: Cerebral perfusion pressure management in head injury. J Trauma 1990, 30:333-940, discussion 940-941.
9. Weed LH, McKibben PS: Experimental alteration of brain bulk. Am J Physiol 1919, 48:531-558.
10. Bullock R, Chesnut RM, Clifton G, Ghajar J, Marion DW, Narayan RK, Newell DW, Pitts LH, Rosner MJ, Wilberger JW: Guidelines for the management of severe head injury. Brain Trauma Foundation. Eur J Emerg Med 1996, 3:109-127.
11. McMullen JE, Aoki H, Brown EB Jr, Kittle CF: Hemodynamic effects of tris (hydroxymethyl) aminomethane. Surg Forum 1965, 16:188-191.
12. Traeger SM, Henning RJ, Dobkin W, Giannotta S, Weil MH, Weiss M: Hemodynamic effects of pentobarbital therapy for intracranial hypertension. Crit Care Med 1983, 11:897-901.
13. The Brain Trauma Foundation. The American Association of Neurological Surgeons. The Joint Section on Neurotrauma and Critical Care. Use of barbiturates in the control of intracranial hypertension. J Neurotrauma 2000, 17:527-530.
14. Nakayama S, Sibley L, Gunther RA, Holcroft JW, Kramer GC: Small-volume resuscitation with hypertonic saline (2,400 mOsm/liter) during hemorrhagic shock. Circ Shock 1984, 13:149-150.
15. Rocha-e-Silva M, Negraes GA, Soares AM, Pontieri V, Loppnow L: Hypertonic resuscitation from severe hemorrhagic shock: patterns of regional circulation. Circ Shock 1986, 19:165-175.
16. Moringas PA, Vettori D, Brambilla GL, Delfini R, Servadei F, Tomei G: Guidelines for the treatment of adults with severe head trauma (part II). Criteria for medical treatment. J Neurosurg Sci 2000, 44:11-18.
17. Kempkis O, Obert C, Mainka T, Heimann A, Strecker U: “Small volume resuscitation” as treatment of cerebral blood flow disturbances and increased ICP in trauma and ischemia. Acta Neurochir Suppl 1996, 66:114-117.
18. Berger S, Schurer L, Hartl R, Daisbock T, Dautermann C, Murr R, Messmer K, Baethmann A: 7.2% NaCl/10% dextran 60 versus 20% mannitol for treatment of intracranial hypertension. Acta Neurochir Suppl (Wien) 1994, 60:494-498.
19. De Vivo P, Del Gaudio A, Cirtella P, Puopolo M, Chiariotti F, Mas- tronardi E: Hypertonic saline solution: a safe alternative to

**Competing interests**

The author(s) declare that they have no competing interests.
mannitol 18% in neurosurgery. Minerva Anestesiol 2001, 67:603-611.

20. Barad AC, Walder B, Rauusin P: [Effects of equiosmolar load of 20% mannitol, 7.5% saline and 0.9% saline on plasma osmo- larity, haemodynamics and plasma concentrations of electrolytes]. Arf Fr Anesth Reanim 2003, 22:18-24.

21. Vieliet R, Albanese J, Thomachat L, Antonini F, Bourgouin A, Alliez B, Martin C: Isovolume hypertonic solutions (sodium cures or mannitol) in the treatment of refractory posttraumatic intracranial hypertension: 2 mL/kg 7.5% saline is more effective than 2 mL/kg 20% mannitol. Crit Care Med 2003, 31:1683-1687.

22. Qureshi AI, Wilson DA, Traystman R: Treatment of elevated intracranial pressure in the pediatric trauma patient. Crit Care Med 2005, 33:1967-1976.

23. Procopio F, Stocchetti N, Citerio G, Berardino M, Beretta L, Della Nada F, Nygren K, Brambilla GL, Delfini R, Servadei F, Tomei G: Guidelines for the treatment of adults with severe head trauma (part I). Initial assessment; evaluation and pre-hospital treatment; current criteria for hospital admission; systemic and cerebral monitoring. J Neurosurg Sci 2000, 44:1-10.

24. Bulger EM, Nathens AB, Rivara FP, Moore M, MacKenzie EJ, Jurk- tokovitch AJ: Management of severe head injury: institutional variations in care and effect on outcome. Crit Care Med 2002, 30:1870-1876.

25. Ghajar J, Hanri RJ, Narayan RK, Iacono LA, Fishk K, Patterson RH: A survey of critical care management of coma, head-injured patients in the United States. Crit Care Med 1995, 23:560-567.

26. Jeevaratnam DR, Menon DK: Mannitol therapy. J Neurosurg Sci 1999, 43:39-48.

27. Matta B, Menon D: Severe head injury in the United Kingdom and Ireland: a survey of practice and implications for management. Crit Care Med 1996, 24:1743-1748.

28. Garcia-Sola R, Pulido P, Capilla P: The immediate and long-term effects of mannitol and glycerol. A comparative experimental study. Acta Neurochir (Wien) 1991, 118:1118-1121.

29. Kofke WA, Tempelhoff R: Increased intracranial pressure in head trauma patients given fentanyl or sufentanil. Anesthesiology 1993, 78:620-621.

30. Fumagalli R, Nakazawa S: [Rebound phenomenon of man- nitol and glycerol: clinical studies]. No To Shinkei 1983, 35:1241-1246.

31. Oken DE: Renal and extrarenal considerations in high-dose mannitol therapy. Ren Fail 1994, 16:147-159.

32. Famularo G: Fentanyl wagon: a puzzle of neurologic pu and life: is mannitol the right drug for the treatment of brain oedema associated with ischaemic stroke? Eur J Emerg Med 1999, 6:363-368.

33. Videen TO, Zaulied AR, Manno EM, Derdeyn CP, Adams RE, Dir- ing MN, Powars WJ: Mannitol bolus preferentially shrinks non-infarcted brain in patients with ischemic stroke. Neurology 2001, 57:2120-2122.

34. Gunnar W, Jonasson O, Merlotti G, Stone J, Barrett J: Head injury and hemorrhagic shock: studies of the blood brain barrier and intracranial pressure after resuscitation with normal saline solution, 3% saline solution, and dextran-40. Surgery 1988, 103:398-407.

35. Gunnar W, Kanet J, Barrett J: Cerebral blood flow following hypertonic saline resuscitation in an experimental model of hemorrhagic shock and head injury. Braz J Med Biol Res 1989, 21:299-303.

36. Gunnar WP, Merlotti GJ, Barrett J, Jonasson O: Resuscitation from hemorrhagic shock. Alterations of the intracranial pres- sure after normal saline, 3% saline and dextran-40. Ann Surg 1986, 204:666-692.

37. Walsh JC, Zhuang J, Shackford SR: A comparison of hypertonic to isotonic fluid in the resuscitation of brain injury and hemor rhagic shock. J Surg Res 1991, 50:284-292.

38. Prough DS, Johnson JC, Poole GV Jr, Stullken EH, Johnston WE Jr, Royeter R: Effects on intracranial pressure of resuscitation from hemorrhagic shock with hypertonic saline versus lac- ted Ringer’s solution. Crit Care Med 1985, 13:407-411.

39. Prough DS, Johnson JC, Stump DA, Stullken EH, Poole GV Jr, Howard G: Effects of hypertonic saline versus lactated Ringer’s solution on cerebral oxygen transport during resusci- tation from hemorrhagic shock. J Neurosurg 1986, 64:627-632.

40. Sheikah MA, Matsuzaka T, Wiesen DH: Cerebral effects of resusci- tation with hypertonic saline and a new low-sodium hypertonic fluid in hemorrhagic shock and head injury. Crit Care Med 1996, 24:1226-1232.

41. Battistella FD, Wiesen DH: Combined hemorrhagic shock and head injury: effects of hypertonic saline (7.5%) resuscitation. J Trauma 1991, 31:181-188.

42. Berger S, Schurer L, Hartl R, Messmer K, Baethmann A: Reduc- tion of post-traumatic intracranial hypertension by hypertonic/ hyperoncotic saline/dextran and hypertonic mannitol. Neuro- surgery 1995, 37:98-107.

43. Prough DS, White JM, Taylor CL, Deal DD, DeWitt DS: Rebound intracranial hypertension in dogs after resuscitation with hypertonic solutions from hemorrhagic shock accompanied by an intracranial mass lesion. J Neurosurg Anesthesiol 1999, 11:102-111.

44. Prochazka V, Jacko S, Bhattacharya P, Herrmann P, Quintel M, Schilling L, Schmiedek P, Schurter L: Hypertonic saline solution for control of elevated intracranial pressure in patients with exhausted response to mannitol and barbiturates. Neurosurgery 1999, 45:58-64.

45. Kish B, Bhattacharya P, Calhoun W, Mauritz W: Hypertonic/hyperoncotic saline reliably reduces ICP in severely head-injured patients with intracranial hypertension. Acta Neurochir Suppl 1997, 70:126-129.

46. Kish B, Bhattacharya P, Calhoun W, Mauritz W: Hypertonic/hyperoncotic saline reliably reduces ICP in severely head-injured patients with intracranial hypertension. Neurosurgery 1997, 40:324-329.

47. Mackay B, Frankel MR: Predictors of early deterioration and mortality in black Americans with spontaneous intracerebral hemorrhage. Stroke 1995, 26:1764-1767.

48. Mackay B, Frankel MR: Predictors of early deterioration and mortality in black Americans with spontaneous intracerebral hemorrhage. Stroke 1995, 26:1764-1767.

49. Clark DE: Hypertonic saline resuscitation of patients with head trauma: experience at a single center. J Trauma 1999, 47:659-665.

50. Hartl R, Schurer L, Goetz C, Berger S, Rohrich F, Baethmann A: The effect of hypertonic fluid resuscitation on brain edema in rabbits subjected to brain injury and hemorrhagic shock. J Trauma 1995, 32:274-279.

51. Shackford SR, Bourguignon PR, Wald SL, Rogers FB, Osler TM, Clark DE: Hypertonic saline resuscitation of patients with head injury: a prospective, randomized clinical trial. J Trauma 1998, 44:50-55.

52. Worthley LJ, Cooper DJ, Jones N: Treatment of resistant intracra- nial hypertension with hypertonic saline. Report of two cases. J Neurosurg 1988, 68:478-481.

53. Kaufmann AM, Cardoso ER: Aversation of vasogenic cerebral edema by multiple-dose mannitol. J Neurosurg 1989, 7:584-589.

54. Wahl M: [Resistance regulation of cerebral vessels]. Fortschr Med 1973, 91:1279.

55. Bosse O, Kuschnisky W, Wahl M: [Effects of osmolality changes on the resistance regulation of the pia mater vessels in the cat]. Pflugers Arch 1972, 332(Suppl 3):R59.

56. Kuschnisky W, Wahl M, Bosse O, Thurau K: Perivascular potas- sium and pH as determinants of local pial arterial diameter in cats. A microapplication study. Circ Res 1972, 31:240-247.

57. Muizelaar JP, Wei EP, Kontos HA, Becker DP: Cerebral blood flow is regulated by changes in blood pressure and in blood viscosity alike. Stroke 1986, 17:44-48.
61. Qureshi AI, Suarez JI: Use of hypertonic saline solutions in treatment of cerebral edema and intracranial hypertension. Crit Care Med 2000, 28:3301-3313.

62. Schwarz S, Georgiadis D, Aschoff A, Schwab S: Effects of hypertonic (10%) saline in patients with raised intracranial pressure after stroke. Stroke 2002, 33:136-140.

63. Tseng MY, Al-Rawi PG, Pickard JD, Rasulo FA, Kirkpatrick PJ: Effect of hypertonic saline on cerebral blood flow in poor-grade patients with subarachnoid hemorrhage. Stroke 2003, 34:1389-1396.